Navigation Links
The Pittsburgh Life Sciences Greenhouse Elects Four New Members to Its Board of Directors
Date:9/13/2007

PITTSBURGH, Sept. 13 /PRNewswire/ -- The Pittsburgh Life Sciences Greenhouse (PLSG), the private/public partnership putting the region's life sciences industry on a fast track for growth, announced that Peter M. DeComo, Chairman and Chief Executive Officer, Renal Solutions, Inc., John A. Kuzmishin, Vice President of Strategic Business Initiatives, UPMC, John L. Miclot, President and Chief Executive Officer, Respironics, and Elizabeth S. Woo, Ph. D., Vice President, Biotechnology, Thermo Fisher Scientific have been elected to the PLSG Board of Directors.

"We are extremely honored that Mr. DeComo, Mr. Kuzmishin, Mr. Miclot and Dr. Woo have agreed to join our board of directors. Their business experience with life science organizations, combined with their significant credentials and achievements, make them a tremendous asset to help guide the PLSG in our efforts to continue to drive innovation and commercialize more life sciences technologies in the region," said John W. Manzetti, PLSG's President and CEO.

About Peter M. DeComo

Mr. DeComo, is a co-founder of Renal Solutions, Inc. (RSI), an innovator in the development of renal dialysis systems for both the institutional and home environments. He serves as the company's Chairman and Chief Executive Officer. Before co-founding RSI, he was the Chief Operating Officer of HemoTherapies Inc., a start-up company in San Diego, commercializing the only FDA cleared Liver Dialysis System. He was previously Senior Vice President of the Specialty Pharmacy Division for Olsten Health Services, now Accredo, a $600 million specialty pharmacy provider. Prior to joining Olsten, Mr. DeComo held numerous senior level positions in the health care industry, launching and commercializing specialized products and services to patients in the home setting. He has served as a Director on the Board of Curative Health Services and is affiliated with a number of healthcare related organizations and advocacy groups. Mr. DeComo received his MS and BS degrees in Healthcare/Business Management from the University of Pittsburgh.

About John A. Kuzmishin

Mr. Kuzmishin is a senior member of the Strategic Business Initiatives group at the University of Pittsburgh Medical Center. His responsibilities include sourcing, structuring and overseeing direct investments as well as general business development for UPMC. Prior to joining UPMC in 2004, Mr. Kuzmishin spent 15 years as a healthcare investment banker, most recently as head of the healthcare investment banking group at Robert W. Baird & Co. (1996 - 2004). Prior to Baird he worked in the investment banking groups at Vector Securities International (1990 - 1996) and Shearson, Lehman Hutton Inc. (1988 - 1990). Mr. Kuzmishin graduated Phi Beta Kappa with honors from The College of Wooster in 1988 earning a Bachelor of Arts in Business Economics.

About John L. Miclot

John L. Miclot became President and CEO of Respironics, Inc., on December 1, 2003. In November 2002 he was appointed the company's Chief Strategic Officer responsible for developing and implementing strategic business and growth initiatives, both domestically and internationally, for each of Respironics' four divisions. In May 2003, he was elected to the Board of Directors. Prior to his position as Chief Strategic Officer he was the President of the Homecare Division from July 1999 to November 2002, where he oversaw strategic direction, sales and marketing, operations as well as research and development for the company's largest division. Miclot joined Respironics in 1998 when it acquired Healthdyne Technologies where he had served as Senior Vice President, Sales and Marketing from 1995-1998. He was appointed Group Vice President, Sleep Disorders, and was quickly promoted to Senior Vice President, Sales, Marketing and Manufacturing.

About Elizabeth S. Woo, Ph.D.

As Vice-President of Sales, Biotechnology Market & Application Specialists Program for Thermo Fisher Scientific, Dr. Woo is responsible for all aspects of sales to the biotechnology/ biopharmaceutical market segment, including sales expenditures, business development, P&L, pricing and financial modeling, contracting, forecasting and territory development. Prior to becoming Vice President, Dr. Woo held positions as Director of Marketing, Senior Director of Business Development, Senior Director of Technical Marketing and Product Manager. Dr. Woo is also an accomplished Bench Scientist. She possesses a Doctorate in Pharmacology from George Washington University Medical Center and a Bachelor of Science Degree in Biological Sciences from Carnegie Mellon University.

About the Pittsburgh Life Sciences Greenhouse (PLSG)

The PLSG invests in and supports the growth of biosciences companies in southwestern Pennsylvania. The PLSG has investment and business growth programs to increase the linkage between research, technology and commercialization; nurture and develop entrepreneurial biosciences enterprises; grow the region's talent pool in the life sciences; and help biosciences firms locate, expand or start-up in the Greater Pittsburgh region. http://www.plsg.com


'/>"/>
SOURCE The Pittsburgh Life Sciences Greenhouse
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Automation of the Eppendorf Perfectprep BAC 96 DNA Kit on the Caliper Life Sciences Sciclone ALH 3000
2. Perscitus Biosciences secures $250K Commerce loan
3. Wisconsin biosciences rise to the challenge
4. Wisconsin professors elected to National Academy of Sciences
5. Quintessence Biosciences advances cancer drug
6. Quintessence Biosciences names new president
7. InvivoSciences receives NIH grant for heart technology
8. Caden Biosciences may signal critical mass
9. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
10. QBI Life Sciences snags $130,000 NIH grant
11. WARF signs licensing pact with BD Biosciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... ... pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights ... (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital ...
(Date:10/10/2017)... CRUZ, Calif. , Oct. 10, 2017 ... grant from the NIH to develop RealSeq®-SC (Single Cell), ... kit for profiling small RNAs (including microRNAs) from single ... Analysis Program highlights the need to accelerate development of ... "New techniques for measuring ...
(Date:10/9/2017)... (PRWEB) , ... October 09, 2017 , ... The award-winning ... to broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. ... is faced with the challenge of how to continue to feed a growing nation. ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... advanced instruments and applications consulting for microscopy and surface analysis, Nanoscience Instruments ... consulting, Nanoscience Analytical offers a broad range of contract analysis services for ...
Breaking Biology Technology:
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
(Date:3/30/2017)... -- The research team of The Hong Kong Polytechnic ... by adopting ground breaking 3D fingerprint minutiae recovery and matching technology, ... accuracy for use in identification, crime investigation, immigration control, security of ... ... A research team led by Dr ...
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
Breaking Biology News(10 mins):